Frankie Fattorini

The EPO ruling affirms bit.bio’s European patent for opti-ox, its proprietary stem cell engineering technology. Credit: Yavdat/ Shutterstock bit.bio has successfully defended the European patent for its opti-ox cell programming technology. After a hearing held on 25 September 2024, the […]

Hanmi will advance its cancer assets through MEDiC’s MCAT platform in return for upfront payments, along with $5m in funding. Credit: sonnim/ Shutterstock Leading Korean biopharma, Hanmi Pharmaceutical, has entered into a research collaboration and financing agreement with Silicon Valley

Anima’s Lighting platform uses machine learning to identify therapeutically relevant mRNAs. Credit: Chaosamran_Studio/ Shutterstock Anima Biotech is utilising machine learning (ML) to investigate the role of messenger RNA (mRNA) in disease, revealing previously unseen pathophysiologies and honing in on new

YL201/IMDELLTRA combination therapy could offer a novel, synergistic action against ES-SCLC. Credit: Sebastian Kaulitzki/ Shutterstock Amgen and MediLink Therapeutics have agreed to a research and supply collaboration to develop a combination therapy for extensive-stage small cell lung cancer (ES-SCLC). Suzhou,

Maria Duca speaking at the ELRIG Drug Discovery conference in London, UK. Credit: Frankie Fattorini/ GlobalData As interest mounts in using RNA as a therapeutic target, a group at the Institute of Chemistry in Nice is overcoming the need for

By targeting a dysfunctional DNA repair system, inhibitors could slow or halt the progression of Huntington’s disease. Image: Shutterstock/ Andrii Yalanskyi. LoQus23 closed a round of Series A financing to advance development of its lead candidate for Huntington’s Disease. The

Ex vivo gene therapy offers a potential one-time, curative solution for a host of genetic diseases. Image: Getty Images/ Perception7 Bristol Myers Squibb (BMS) has agreed to a research and licensing deal with Prime Medicine to develop ex vivo T